1. Home
  2. CHRS vs SLE Comparison

CHRS vs SLE Comparison

Compare CHRS & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.13

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Logo Super League Enterprise Inc.

SLE

Super League Enterprise Inc.

HOLD

Current Price

$5.03

Market Cap

177.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHRS
SLE
Founded
2010
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Services-Misc. Amusement & Recreation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
177.7M
177.4M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
CHRS
SLE
Price
$1.13
$5.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$5.51
★ $60.00
AVG Volume (30 Days)
★ 1.1M
245.9K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 472.00
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,064,000.00
Revenue This Year
$73.08
$24.86
Revenue Next Year
$30.94
$49.77
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 90.41
52 Week Low
$1.09
$0.48
52 Week High
$2.62
$9.00

Technical Indicators

Market Signals
Indicator
CHRS
SLE
Relative Strength Index (RSI) 37.82 58.81
Support Level N/A $2.66
Resistance Level $1.53 $5.24
Average True Range (ATR) 0.09 0.51
MACD -0.02 0.04
Stochastic Oscillator 0.00 55.79

Price Performance

Historical Comparison
CHRS
SLE

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

About SLE Super League Enterprise Inc.

Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.

Share on Social Networks: